CervoMed Inc. (CRVO)
2.12
0.08 (3.92%)
At close: Jan 14, 2025, 3:59 PM
2.06
-2.78%
After-hours Jan 14, 2025, 04:56 PM EST
undefined% (undefined)
| Bid | 1.99 |
| Market Cap | 17.50M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.17 |
| PE Ratio (ttm) | -0.98 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.14 |
| Volume | 116,163 |
| Avg. Volume (20D) | 430,250 |
| Open | 2.04 |
| Previous Close | 2.04 |
| Day's Range | 2.01 - 2.15 |
| 52-Week Range | 1.80 - 26.38 |
| Beta | undefined |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts....
Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2008
Employees 8
Stock Exchange NASDAQ
Ticker Symbol CRVO
Website https://www.cervomed.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CRVO stock is "Hold." The 12-month stock price forecast is $40, which is an increase of 1786.79% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
CervoMed Inc. is scheduled to release its earnings on Mar 31, 2025,
during market hours.
Analysts project revenue of $1.92M, reflecting a -22.92% YoY shrinking and earnings per share of -0.58, making a -62.58% decrease YoY.
Analysts project revenue of $1.92M, reflecting a -22.92% YoY shrinking and earnings per share of -0.58, making a -62.58% decrease YoY.
1 month ago ·
Source
-78.93%
CervoMed shares are trading lower after the compan...
Unlock content with
Pro Subscription
1 month ago ·
Source
+14.66%
CervoMed shares are trading higher after the company announced its orval investigational drug Neflamapimod was granted orphan drug designation status by the FDA for the treatment of frontotemporal dementia.
